This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy

This study has been completed.
Information provided by (Responsible Party):
Virdi Eye Clinic Identifier:
First received: November 7, 2011
Last updated: May 1, 2016
Last verified: May 2016
This study will compare the effect of two topical non-steroidal antiinflammatory agents to control pain after photorefractive keratectomy (PRK) eye surgery.

Condition Intervention Phase
Myopia Drug: Bromfenac Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Bromday (Bromfenac Ophthalmic Solution)0.09% QD vs Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Control of Pain and Epithelial Healing Post (PRK)

Resource links provided by NLM:

Further study details as provided by Virdi Eye Clinic:

Primary Outcome Measures:
  • Post-PRK pain [ Time Frame: 7 days ]

Secondary Outcome Measures:
  • Post-PRK epithelial healing [ Time Frame: 7 days ]

Enrollment: 20
Study Start Date: May 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Nepafenac Drug: Bromfenac
Bromfenac 0.09% 1 drop in study eyes q day
Other Name: Bromday


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All patients undergoing photorefractive keratectomy in both eyes

Inclusion Criteria:

  • male or female at least 18 years of age,
  • no other ocular studies with 15 days prior to dosing,
  • BCVA 20/200 or better,
  • return for study visits and follow instructions from investigator and staff,
  • self administer test article

Exclusion Criteria:

  • Ocular inflammation,
  • hypersensitivity to bromfenac or nepafenac,
  • any corneal pathology,
  • have had radial keratotomy,
  • corneal transplant or corneal refractive surgery in the last two years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01475877

United States, Illinois
Virdi Eye Clinic and Laser Vision Center
Rock Island, Illinois, United States, 61201
Sponsors and Collaborators
Virdi Eye Clinic
Principal Investigator: Navaneet S Borisuth, MD,PhD Virdi Eye Clinic
  More Information

Responsible Party: Virdi Eye Clinic Identifier: NCT01475877     History of Changes
Other Study ID Numbers: MAC-02-11
Study First Received: November 7, 2011
Last Updated: May 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: In the observational study conducted, there was no significant difference in pain levels or epithelial healing of post-photorefractive keratectomy patients who were treated with bromfenac 0.09% or nepafenac 0.1%

Keywords provided by Virdi Eye Clinic:
epithelial healing,

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on September 21, 2017